Abstracts Archive - Page 455 of 2607 - ACR Meeting Abstracts

Abstract Number: 1925 • ACR Convergence 2023
Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study
Aleksander Lenert¹, Robyn Domsic², Karmela Kim Chan³, Melissa Oliver⁴, Jisna Paul⁵, Courtney Kremer⁶, Emma Leisinger¹, Helena Abodeely¹, Sandy Hong⁶, Arundathi Jayatilleke⁷, Petar Lenert⁸, T. Shawn Sato¹, Yongdong (Dan) Zhao⁹, Jonathan Templin¹, Mary Vaughan-Sarrazin¹, Daniel Solomon¹⁰ and Polly Ferguson¹¹, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³Hospital For Special Surgery, New York, NY, ⁴Indiana University, Indianapolis, IN, ⁵Ohio State University Hospital, Columbus, OH, ⁶University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁷Temple University, Philadelphia, PA, ⁸University of Iowa Hospitals and Clinics, Iowa City, IA, ⁹University of Washington, Seattle, WA, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Musculoskeletal pain is a key symptom experienced by patients with SAPHO and chronic nonbacterial osteomyelitis (SAPHO-CNO), yet its relation to disease activity assessment remains…
Abstract Number: 1933 • ACR Convergence 2023
Analysis of IgG4-Related Disease in a Diverse Long Island Population: Insights from the Rheumatology Clinic
Young Min Cho¹, Galina Marder², Koushik Sangaraju³, Lara El Khoury², Kourosh Shargani⁴ and Jevon Fragoso⁵, ¹Northwell, Glen Cove, NY, ²Northwell, Great Neck, NY, ³Staten Island University Hospital - Northwell Health, Staten Island, NY, ⁴Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, ⁵Northwell, Queens, NY
Background/Purpose: IgG4-related disease (IgG4RD) is an immune-mediated disease characterized by dense lymphoid-lymphoplasmacytic infiltrates with high IgG4-positive plasma cells with heterogeneous clinical manifestations. The data on…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 1937 • ACR Convergence 2023
Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Frank Cai¹, Anisha Paulson¹, Amy Wozniak², Emily Gilbert² and Rochella Ostrowski², ¹Loyola University Medical Center, Oak Park, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
Abstract Number: 1929 • ACR Convergence 2023
Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience
Zeynep Toker Dincer¹, Sejla Karup², Erkin Yilmaz¹, Osman Corbali¹ and Serdal Ugurlu¹, ¹Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of…
Abstract Number: 1921 • ACR Convergence 2023
Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department
Herman Mann¹, Blanka Stiburkova², Katerina Pavelcova¹, Monika Belickova³, Cyril Salek³, Jana Juhaszova¹ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Praha 2, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Hematology and Blood Transfusion, Praha 2, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: VEXAS (vacuoles, E1 activating enzyme, X-linked, auto-inflammatory, somatic) syndrome is a clinically serious and potentially fatal adult-onset disease caused by somatic mutations in the…
Abstract Number: 1945 • ACR Convergence 2023
Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals
Arturo Llobell¹, Inigo Gonzalez-Mazon², carmen secada³, Adrian Martin-Gutierrez³, Almudena García-Castaño³, Enrique Gallardo⁴, Soledad Retamozo⁵, Antonio Gomez-Centeno⁶, Luis Fernandez-Morales⁴, Jordi Gratacos Masmitja⁷ and Ricardo Blanco⁸, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Parc Taulí University Hospital, Sabadell, Spain, ⁵Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, ⁶Parc Taulí Hospital Universitari, Sabadell, Spain, ⁷University Hospital Parc Taulí, Sabadell, Spain, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
Abstract Number: 1942 • ACR Convergence 2023
Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases
Carmen Lasa¹, Joy Selene Osorio², David Martínez-Lopez³, Carmen Alvarez Reguera⁴, Virginia Portilla⁵, Jose Cifrian⁶, Ivan Ferraz Amaro⁷ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Patients with rheumatic immune-mediated inflammatory diseases (rheumatic-IMID) with latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at anincreased risk of developing active tuberculosis…
Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Tegveer Sandhu¹, Lea Meir², Nicole Ng¹, Lila Klein¹, Jigna Zatakia¹, Maria Padilla¹ and Ioannis Tassiulas¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…
Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Koushan Kouranloo¹, Mrinalini Dey², Veronica Yioe³, Lisa G Spencer³ and Caroline V Cotton⁴, ¹Rheumatology & Internal Medicine Trainee- Surrey, UK. Education fellow University of Liverpool, Liverpool, United Kingdom, ²Queen Elizabeth Hospital, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom, ³Liverpool Regional Lung Disease Service, Aintree Hospital, Lower Lane, Liverpool, United Kingdom, ⁴Department of rheumatology, Liverpool University NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 1869 • ACR Convergence 2023
FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients
Andreas Wiggers Nielsen¹, Ib Tønder Hansen², Berit Dalsgaard Nielsen³, Søren Geill Kjær⁴, Jesper Blegvad-Nissen⁴, Christian Møller Sørensen³, Ellen-Margrethe Hauge¹, Lars Christian Gormsen² and Kresten Krarup Keller¹, ¹Aarhus University Hospital, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus N, Denmark, ³Department of Internal Medicine, Horsens, Denmark, ⁴Diagnostic Centre, Silkeborg, Denmark
Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients…
Abstract Number: 1851 • ACR Convergence 2023
Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar
Chiara Gasteiger¹, Maria Lobo², Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Transitioning patients with rheumatic diseases to biosimilars has become common to reduce healthcare costs and improve patient access to biologic therapies. However, it is…
Abstract Number: 0208 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
Angela Bobak¹, Emely Pimentel¹, Jordan Jackson², Celia Gray³, Hema Srinivasan³, Andrea Berger³ and David Bulbin³, ¹Geisinger Medical Center Internal Medicine Residency, Danville, PA, ²Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients. Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Faiza Javed, Tony Mangino and Paramarajan Piranavan, University of Kentucky College of Medicine, Lexington, KY
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].